CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies, today announced that Philip Gregory, D. Phil., is joining the company as its Chief Scientific Officer and a member of the leadership team.
Help employers find you! Check out all the jobs and post your resume.
